NanoVibronix Announces Distribution Agreement with Dukehill Healthcare in Australia
NanoVibronix, Inc. (NASDAQ: NAOV), a leading medical technology company specializing in non-invasive therapeutic devices, has announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. (“Dukehill”), a move that strengthens the presence of NanoVibronix’s innovative devices in Australia.
Dukehill, headquartered in Queensland, has historically focused its clinical projects and sales efforts primarily within Queensland and New South Wales. However, the expanded agreement now broadens the distribution of NanoVibronix’s products across all states in Australia, with significant growth expected in South Australia and Victoria.
This expansion comes in response to a rising number of inquiries and orders from healthcare facilities in these regions. A key driver of this increased interest is the recent publication of an independent study, which highlighted the effectiveness of NanoVibronix’s UroShield device in reducing catheter-associated complications and improving patient outcomes. The positive findings from this study are expected to further accelerate sales and adoption of UroShield across the country.
Brian Murphy, Chief Executive Officer of NanoVibronix, expressed enthusiasm about the renewed partnership with Dukehill, saying, “We believe the renewal of our distribution partnership with Dukehill underscores the growing recognition of UroShield’s effectiveness in improving patient care and our commitment to making this technology more widely accessible. With Dukehill’s expanded presence in Australia and the heightened awareness generated by the recent study, we are confident in UroShield’s continued success in the market. This agreement with Dukehill is expected to enable more patients and healthcare providers to experience the benefits of our innovative technology.”
Toni Hill, Director of Dukehill, shared her excitement about the expanded partnership, stating, “We are excited to strengthen our partnership with NanoVibronix and bring UroShield to a wider population across Australia. The growing interest in UroShield, combined with the positive study results, highlights the device’s potential to transform the management of urinary catheters and improve the quality of life for patients.”
As part of its expanded role, Dukehill will showcase UroShield’s benefits at the upcoming 33rd National Conference on Incontinence, hosted by Continence Health Australia, which will take place in Hobart in May 2025. This conference will bring together clinicians from across Australia, providing an opportunity to discuss the findings from the recent independent study. The conference program and exhibition will further reinforce UroShield’s clinical efficacy and patient benefits. The event promises to serve as an important platform for educating healthcare professionals about the device’s potential to reduce complications and improve patient outcomes in catheter management.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development operations in Nesher, Israel. The company specializes in the development of medical devices that utilize its patented low-intensity surface acoustic wave (SAW) technology.
This proprietary technology allows the creation of low-frequency ultrasound waves that can be used for various medical applications, including the disruption of biofilms and bacterial colonization, as well as pain relief. One of the key advantages of NanoVibronix’s devices is that they can be used at home, without the continuous need for medical professionals. The company’s primary products include PainShield® and UroShield®, which are portable, non-invasive devices suitable for use in a variety of care settings, both at home and in healthcare facilities.
UroShield® specifically addresses the challenges associated with urinary catheter use, including reducing the risk of catheter-associated infections and improving the overall comfort and well-being of patients. Its effectiveness in managing complications related to catheters has been validated through independent clinical studies, positioning it as a valuable tool for both patients and healthcare providers.
NanoVibronix’s continued innovation in the medical technology field, paired with its growing global distribution network, positions the company to make a significant impact on patient care. The collaboration with Dukehill Healthcare in Australia is just one example of how NanoVibronix is expanding the reach of its groundbreaking therapeutic devices worldwide.
As NanoVibronix works to address critical healthcare challenges through non-invasive treatments, the company remains committed to improving patient outcomes and expanding access to its technologies across diverse global markets.
